Gonadotropin-releasing hormone agonist use to guide diagnosis and treatment of autoimmune progesterone dermatitis.

Document Type

Article

Publication Date

5-1-2015

Institution/Department

Obstetrics & Gynecology

Journal Title

Obstetrics and gynecology

MeSH Headings

Autoimmune Diseases, Delayed-Action Preparations, Dermatitis, Female, Gonadotropin-Releasing Hormone, Humans, Injections, Intramuscular, Leuprolide, Luteal Phase, Middle Aged, Progesterone

Abstract

BACKGROUND: Autoimmune progesterone dermatitis is a catamenial disorder traditionally diagnosed by subcutaneous or intramuscular progesterone challenge. Little has been reported regarding the use of a gonadotropin-releasing hormone (GnRH) agonist with a progestin add-back challenge to diagnose and guide management of this condition.

CASE: A 50-year-old premenopausal woman presented with cyclic facial rash minimally responsive to standard treatment. Symptoms improved with depot leuprolide acetate and worsened with add-back progesterone therapy. Hysterectomy and oophorectomy were performed with resolution of symptoms. This surgery eliminated endogenous progesterone and permitted estrogen replacement to treat vasomotor symptoms experienced with GnRH agonist therapy.

CONCLUSION: This case of autoimmune progesterone dermatitis exemplifies the utility of GnRH agonists with a steroid add-back challenge for diagnosing catamenial disorders and guiding treatment.

ISSN

1873-233X

First Page

1114

Last Page

1116

Share

COinS